The question of whether the herpes zoster vaccine—commonly known as the shingles vaccine—can reduce the risk of dementia, including Alzheimer’s disease, has gained increasing attention in recent years. Recent reports and studies are fueling a growing body of evidence suggesting a potential link between vaccination against shingles and a decreased incidence of dementia. Even as the exact mechanisms are still being investigated, the findings offer a promising avenue for preventative strategies against neurodegenerative diseases.
For decades, scientists have debated the potential connection between viral infections and the development of dementia. The idea that viruses might trigger or exacerbate Alzheimer’s pathology has been met with conflicting epidemiological findings, making it a complex area of research. However, emerging data is strengthening the hypothesis that controlling viral infections, such as shingles, could have a protective effect on cognitive health. Here’s particularly relevant given the increasing global burden of both shingles and dementia, prompting a search for modifiable risk factors.
Shingles and the Brain: Unraveling the Connection
Shingles, or herpes zoster, is a painful rash caused by the reactivation of the varicella-zoster virus – the same virus that causes chickenpox. After a chickenpox infection, the virus remains dormant in nerve cells. As people age, or if their immune system weakens, the virus can reactivate, leading to shingles. The pain associated with shingles can be debilitating, and even after the rash clears, a condition called postherpetic neuralgia can cause chronic pain. But the implications of shingles may extend beyond the immediate discomfort.
Researchers are now exploring how the reactivation of the varicella-zoster virus might contribute to neuroinflammation and neuronal damage, potentially increasing the risk of dementia. The virus can affect the trigeminal ganglion, a major nerve center in the head, and its reactivation may trigger an immune response that impacts brain health. A systematic review and meta-analysis published in Brain, Behavior, and Immunity in February 2024 investigated the association between herpes zoster vaccination and dementia risk. The study, conducted by researchers from Tribhuvan University in Nepal, Westchester Medical Center in Fresh York, and other institutions, aimed to synthesize existing evidence on this topic. The full study can be found in the journal.
Evidence from Research: Vaccination and Dementia Risk
The meta-analysis, encompassing multiple studies, indicated a decreased risk of dementia among individuals who received the herpes zoster vaccine. The findings align with previous research suggesting a protective effect. Alzforum reports that these findings support the idea that viral infections can play a role in Alzheimer’s disease pathology in some individuals. The researchers propose that the vaccine may reduce the risk of dementia through several mechanisms. One possibility is that the vaccine directly reduces the reactivation of the varicella-zoster virus, thereby minimizing neuroinflammation. Another hypothesis is that the vaccine has an indirect effect, modulating the immune response and promoting neuroprotection.
A report from the Fondation Alzheimer, published in July 2025 and updated in September 2025, highlights that studies suggest the shingles vaccine could reduce the risk of dementia by as much as 20%. The Fondation Alzheimer article details that the vaccine is highly effective in reducing the recurrence of the virus, particularly in individuals with weakened immune systems, and consequently reduces skin lesions and associated pain. Crucially, the vaccine appears to possess a neuroprotective action beyond its effects on skin lesions.
How Does the Vaccine Offer Protection?
The precise mechanisms by which the shingles vaccine might protect against dementia are still under investigation. However, several theories are being explored. One key aspect is the vaccine’s ability to boost the immune system’s response to the varicella-zoster virus. By strengthening the immune response, the vaccine may help to prevent the virus from reactivating and causing inflammation in the nervous system. This reduction in neuroinflammation could, in turn, protect against neuronal damage and cognitive decline.
the vaccine may have a broader immunomodulatory effect, influencing the overall immune response in the body. This could help to reduce chronic inflammation, which is increasingly recognized as a contributing factor to many age-related diseases, including dementia. The vaccine’s impact on inflammation may extend beyond the nervous system, potentially benefiting overall brain health.
Who Should Consider the Shingles Vaccine?
Currently, the Centers for Disease Control and Prevention (CDC) recommends that healthy adults 50 years and older receive two doses of the recombinant zoster vaccine (RZV), Shingrix. The vaccine is highly effective in preventing shingles and postherpetic neuralgia. While the primary goal of vaccination is to prevent shingles, the potential cognitive benefits are an added advantage. Individuals with weakened immune systems due to medical conditions or treatments should consult with their healthcare provider to determine if the vaccine is appropriate for them.
It’s important to note that the shingles vaccine is not a guaranteed prevention for dementia. Dementia is a complex condition with multiple risk factors, including genetics, lifestyle, and other medical conditions. However, vaccination against shingles may be a valuable tool in reducing the risk, particularly for individuals who are susceptible to the virus.
Current Limitations and Future Research
While the evidence linking shingles vaccination to reduced dementia risk is growing, it’s important to acknowledge the limitations of current research. Many studies are observational, meaning they can show an association but cannot prove causation. Further research, including randomized controlled trials, is needed to confirm these findings and to fully understand the underlying mechanisms. Researchers are also investigating whether earlier vaccination, before the age of 50, might offer even greater protection against dementia.
Ongoing studies are exploring the impact of the vaccine on different biomarkers of Alzheimer’s disease, such as amyloid plaques and tau tangles, to gain a deeper understanding of its neuroprotective effects. Researchers are investigating whether the vaccine’s benefits extend to individuals with pre-existing cognitive impairment. The results of these studies will provide valuable insights into the potential of shingles vaccination as a preventative strategy against dementia.
What Which means for Public Health
The potential link between shingles vaccination and dementia risk has significant implications for public health. If further research confirms these findings, it could lead to recommendations for broader vaccination programs aimed at reducing the burden of dementia. Increasing vaccination rates against shingles could not only prevent a painful and debilitating illness but also potentially protect against cognitive decline.
Public health campaigns could emphasize the potential cognitive benefits of the vaccine, alongside its primary role in preventing shingles. Healthcare providers could also play a key role in educating patients about the potential benefits of vaccination and encouraging those who are eligible to get vaccinated. The integration of shingles vaccination into routine healthcare practices could be a cost-effective strategy for promoting brain health and reducing the incidence of dementia.
The next steps in this research involve larger, more comprehensive studies to confirm the observed associations and to elucidate the underlying biological mechanisms. Researchers are also exploring the potential for developing new vaccines or therapies that target the varicella-zoster virus and its impact on brain health. Continued investment in research is crucial to unlocking the full potential of shingles vaccination as a preventative measure against dementia.
The evolving understanding of the connection between viral infections and neurodegenerative diseases underscores the importance of proactive health management and preventative strategies. Staying informed about the latest research and discussing vaccination options with your healthcare provider are essential steps in protecting your cognitive health as you age. Share this article with your network to raise awareness about this important topic and encourage informed discussions about preventative healthcare.